AXSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Axsome Therapeutics Inc (AXSM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, bullish technical indicators, favorable analyst ratings with increasing price targets, and a high conviction for FDA approval of a key drug. Although the financials show a net income loss, the revenue growth and gross margin improvement indicate strong operational progress.
The technical indicators for AXSM are bullish. The MACD is above 0 and positively contracting, indicating continued upward momentum. The RSI is at 82.18, signaling overbought conditions, but this is typical for a strong uptrend. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near resistance levels (R1: 183.27, R2: 187.961), suggesting potential for further upside.
High conviction from analysts for FDA approval of AXS-05 for Alzheimer's Disease Agitation by April 30, with potential for $2 billion in incremental sales.
Multiple analysts have raised price targets recently, with UBS at $259, Guggenheim at $245, and others showing strong confidence in the company's growth prospects.
Revenue grew by 65.03% YoY in Q4 2025, and gross margin improved to 92.89%.
Net income dropped by 61.88% YoY, and EPS declined by 63.64%, reflecting ongoing losses.
The stock is overbought (RSI: 82.18), which could lead to short-term pullbacks.
No significant insider or hedge fund trading trends, and no recent congress trading data.
In Q4 2025, Axsome Therapeutics reported a 65.03% YoY revenue increase to $195.99M, highlighting strong growth. However, net income dropped to -$28.56M (-61.88% YoY), and EPS fell to -0.56 (-63.64% YoY). Gross margin improved to 92.89%, up 3.45% YoY, indicating operational efficiency despite the losses.
Analysts are overwhelmingly positive on AXSM, with multiple firms raising price targets recently. UBS has the highest target at $259, citing high conviction in FDA approval for AXS-05. Guggenheim, RBC Capital, and others also raised targets, emphasizing strong product performance, pipeline growth, and operating leverage. The consensus is a strong Buy.
